Form 4: CATX Director Williamson Granted 50,000 Stock Options

Perspective Therapeutics Director Robert F. Williamson III received an annual equity award of 50,000 stock options, vesting in March 2027.

Summary

• Robert F. Williamson III, a Director of Perspective Therapeutics, Inc. (CATX), was granted 50,000 stock options.
• The options have an exercise price of $5.35 per share.
• The grant date for these options was March 2, 2026, and they represent his annual equity award for 2026.
• The options will vest in full on March 2, 2027, contingent upon Mr. Williamson's continued service.
• The expiration date for these stock options is March 2, 2036.
• Following this transaction, Mr. Williamson beneficially owns 50,000 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While a routine compensation event, it signifies continued director engagement and aligns their financial interests with the company's long-term performance, which is generally favorable for shareholders.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• This is a routine annual equity award, indicating stable compensation practices for the board.

Negatives

• NA

Risks

• NA

Future Outlook

The options are set to vest in full on March 2, 2027, provided the reporting person continues their service, indicating a future milestone for the award.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice across industries, particularly in biotechnology and growth-oriented companies like Perspective Therapeutics. This method of compensation is designed to tie director incentives directly to the company's stock performance, fostering long-term commitment and alignment with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as an annual equity award is a standard practice for compensating non-employee directors in publicly traded companies, comparable to practices at peers in the biotechnology sector.
• The vesting schedule, typically over one to three years, and a ten-year expiration period for options are also common industry benchmarks for such awards.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, specifically director compensation, which was approved by the Issuer's Board of Directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The 50,000 stock options will vest in full on March 2, 2027, subject to Robert F. Williamson III's continued service.

Key Dates

Keywords

Perspective Therapeutics, CATX, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Award